Publication

Determination of the Relative Bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance Manufactured by supercritical fluids and micronization

Richardson, Catherine H.
; 
de Matas, Marcel
; 
Hosker, K.
; 
Mukherjee, R.
; 
Wong, Ian
; 
Chrystyn, Henry
Publication Date
2007
End of Embargo
Supervisor
Keywords
Dry powder inhalers, Fine particle dose, Relative lung bioavailability, Supercritical fluids, Urinary salbutamol
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Additional title
Abstract
Purpose The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS¿) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler¿, Innovata Biomed). Materials and Methods Twelve healthy volunteers and 11 mild asthmatic patients completed separate four-way randomised cross-over studies, assessing the relative bioavailability of salbutamol sulfate (urinary excretion method), formulated as SEDS¿ particles (three batches) and micronized particles (Asmasal¿ inhaler, UCB Pharma Ltd). Post-treatment improvements in patient lung function were assessed by measuring FEV1. Physicochemical evaluation of the three SEDS¿ batches revealed inter-batch differences in particle size and shape. Results There was no significant difference in the relative lung bioavailability of salbutamol and its bronchodilator response between the best performing SEDS¿ formulation and the Asmasal¿ inhaler in volunteers and patients, respectively. SEDS¿ salbutamol sulfate showing wafer like morphology gave greater fine particle dose, relative lung bioavailability and enhanced bronchodilation compared to other SEDS¿ batches containing elongated particles. Conclusions Active Pharmaceutical Ingredient (API) manufactured using supercritical fluids and delivered by DPI can provide similar lung bioavailability and clinical effect to the conventional micronized commercial product. Product performance is however notably influenced by inter-batch differences in particle characteristics.
URI
http://hdl.handle.net/10454/3813
Version
No full-text in the repository
Citation
Richardson, C.H., De Matas, M., Hosker, K. and Mukherjee, R. et al. (2007). Determination of the Relative Bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance Manufactured by supercritical fluids and micronization. Pharmaceutical Research. Vol. 24, No. 1, pp. 2008-2017.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1007/s11095-007-9328-y
Type
Article
Qualification name
Notes